Connect with us

Technology

Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa

Published

on

SINGAPORE, June 24, 2024 /PRNewswire/ — Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)’ solid tumour molecular profiling services in the Middle East and Africa (MEA). Caris is the leading next-generation AI TechBio company and precision medicine pioneer. This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA). Juniper is now poised to offer Caris’ advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.

Caris’ best-in-class molecular profiling, combined with proprietary artificial intelligence, provides more precise and individualized cancer treatments. This profiling approach assesses DNA, RNA, and proteins, revealing a molecular blueprint that identifies treatment options specific to each patient’s cancer. Caris has developed the world’s largest and most informative platform for cancer analysis, featuring the most advanced tumour profiling available, including Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes. By analysing biomarkers found in tumours, Caris helps healthcare providers make informed choices for personalised care.

Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper’s collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced therapies is limited.

Raman Singh, Founder and Chief Executive Officer (CEO) of Juniper Biologics, spoke on the successful acquisition: “Caris molecular profiling bridges the gap between tumour biology and cancer treatments, guiding precision medicine through personalised treatment selection for physicians and their patients. Our exclusive partnership with Caris Life Sciences to distribute this service in the Middle East and Africa will significantly empower healthcare professionals to make informed decisions for their patients. This service enables oncologists to recommend highly personalised treatments that specifically target a patient’s cancer, thereby improving and expanding their care options. This targeted approach offers patients, particularly those with rare or aggressive cancers, an improved quality of life.”

“Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics,” said Caris President David Spetzler, MS, PhD, MBA. “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”

This partnership marks a significant milestone in expanding access to personalised medicine and advanced cancer treatment technologies in the Middle East and Africa.

About Juniper Biologics

Backed by The Sylvan Group, Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients, by building a growing presence in Oncology and Oncology Supportive Care, Rare/Orphan Diseases and Gene Therapy. It was founded on a vision to provide treatments for unmet medical needs focused on specialist therapy areas in which it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, Middle East, and Africa.

Website: https://www.juniperbiologics.com/

LinkedIn: https://www.linkedin.com/company/juniper-biologics

About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyse and unravel the molecular complexity of disease. This convergence of sequencing power, big data, and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection, and drug development.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia, and other international markets. To learn more, please visit CarisLifeSciences.com.

View original content:https://www.prnewswire.co.uk/news-releases/juniper-biologics-expands-distribution-rights-for-caris-life-sciences-molecular-profiling-in-the-middle-east-and-africa-302179771.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Published

on

By

The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor

NEW YORK, July 22, 2026 /PRNewswire/ — DarioHealth Corp. (NASDAQ: DRIO) (the “Company,” “DarioHealth” or “Dario”), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered direct offering priced at-the-market under Nasdaq rules (the “Offering”). A member of the Company’s Board of Directors participated in the Offering by purchasing 14,430 shares of the Company’s common stock at a purchase price of $6.93 per share. The gross proceeds from the Offering are expected to be approximately $23.5 million, before deducting placement agent fees and other estimated Offering expenses.

The closing of the offering is expected to occur on or about July 23, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital, investments, acquisitions, and general corporate purposes. 

The Offering was priced at-the-market under Nasdaq rules. Existing long-term Dario institutional investors are participating alongside new fundamental investors, reflecting continued support for the Company’s strategic direction and ongoing business transformation into an AI-powered platform for the management of multiple chronic conditions.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

The securities described above are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-294454) which became effective on March 27, 2026. The Offering is being made only by means of a prospectus which is part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the Offering will be filed with the Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website located at http://www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company’s integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario’s AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when discussing the expected timing of the closing of the offering and the expected use of proceeds. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-announces-pricing-of-a-23-5-million-registered-direct-offering-of-common-stock-priced-at-the-market-under-nasdaq-rules-302832102.html

SOURCE DarioHealth Corp.

Continue Reading

Technology

Mattermost Launches Professional Certification for Engineers Operating Mission-Critical Communications Infrastructure

Published

on

By

Mattermost has launched its new Professional Certification, a high‑level credential designed for engineers, integrators, and administrators who deploy and operate Mattermost in mission‑critical, high‑security environments. Building on the strong adoption of the Associate Certification, the Professional tier validates advanced expertise in high‑availability architecture, identity integration, compliance, workflow automation, and operations in air‑gapped and classified networks. With early demand across defense, Federal, and enterprise sectors, this certification strengthens operational readiness, accelerates ATO timelines, and ensures organizations can confidently staff secure Mattermost deployments.

New Certification Tier Validates Advanced Deployment and Operational Expertise for Engineers in Defense, Federal and Security-Critical Environments

PALO ALTO, Calif., July 22, 2026 /PRNewswire-PRWeb/ — Six months after launching its first technical certification, Mattermost, the secure collaboration platform built for the world’s most critical operations, has certified hundreds of engineers across defense and federal governments – and today raises the bar with the launch of its Professional Certification tier — designed for engineers, integrators and administrators who deploy and operate Mattermost in defense, Federal and enterprise environments.

The Professional Certification builds on the Mattermost Associate Technical Certification, which launched in January 2026. Since launching, the Associate program has seen strong adoption with more than 125 engineers certified across partner and customer organizations, with engineers proudly sharing their credentials on LinkedIn as a signal of operational credibility in their markets.

The Professional tier validates the technical depth required to deploy and operate Mattermost in high-scale mission-critical environments, including high-availability architecture, identity integration, compliance controls and workflow automation for security-sensitive operations. Labs are hands-on and embedded directly in the learning environment. No other platform in this space offers this level of operational certification for air-gapped and classified environments.

“The Mattermost Certification Program reflects the operational standards our Government customers require to accomplish their missions,” said Corey Hulen, CEO of Mattermost Federal. “The environments they operate in don’t have a margin for error — when an engineer shows up to deploy or support Mattermost in a classified network or an air-gapped facility, they need to have already proven they can handle it. That’s not a nice-to-have. It’s a requirement.”

Designed for the Most Demanding Environments

Mattermost serves defense agencies, Federal departments and global enterprises that require communications infrastructure to operate where commercial cloud platforms cannot — including classified networks, air-gapped installations and disconnected forward operating environments. The Professional Certification reflects the operational standards these deployments require. For mission operators, that translates directly into operational readiness; faster Authority to Operate (ATO) timelines, reduced deployment risks, and a qualified talent pipeline that program offices cna hire and staff against with confidence.

The certification is available to SI and implementation partners and customer administrators managing production deployments. Early demand has been strong, with more than 25 organizations enrolling teams across defense, Federal and enterprise sectors enrolling teams in both the Associate and Professional programs.

“Carahsoft and our reseller partners are committed to connecting Government agencies with the innovative technologies they need to achieve their missions,” said Michael Shrader, Vice President of Intelligence and Innovative Solutions at Carahsoft. “The Mattermost Professional Certification Program helps ensure Public Sector organizations can confidently deploy and operate Mattermost in secure, high-performance environments.”

Availability

The Mattermost Professional Certification is available at certifications.mattermost.com. Engineers who have completed the Associate Technical Certification are encouraged to enroll directly. Experienced engineers may also attempt the Professional tier without the Associate prerequisite. Through Mattermost’s partnership with Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, its services are available through Government-approved contracts and Carahsoft’s reseller network.

Mattermost’s solutions are available through Carahsoft’s GSA Schedule No. 47QSWA18D008F, SEWP V contracts NNG15SC03B and NNG15SC27B, ITES-SW2 Contract W52P1J-20-D-0042, OMNIA Partners Contract #R240303 and The Quilt Master Service Agreement Number MSA05012019-F. For more information, contact the Carahsoft Team at (571) 662-4800 or Mattermost@carahsoft.com. Explore Mattermost’s solutions here.

About Mattermost

Mattermost is the secure, open-source collaboration platform built for technical teams in high-stakes, high-security environments. Trusted by defense agencies, government departments, and global enterprises, Mattermost is designed to operate where other platforms can’t — on-premises, air-gapped, and in the most demanding operational conditions on earth. Mattermost’s mission is to empower the people the world relies on. Learn more at mattermost.com.

Media contact:

Mattermost:

Rosa Lear

a-rosa.lear@mattermost.com

Media Contact

Rosa Lear, Mattermost, 1 4087574362, a-rosa.lear@mattermost.com, https://mattermost.com/

View original content to download multimedia:https://www.prweb.com/releases/mattermost-launches-professional-certification-for-engineers-operating-mission-critical-communications-infrastructure-302831659.html

SOURCE Mattermost

Continue Reading

Technology

Axcelis Announces Timing and Availability of Second Quarter 2026 Results and Conference Call

Published

on

By

BEVERLY, Mass., July 22, 2026 /PRNewswire/ — Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry will release financial results for the second quarter of 2026 before the opening of the market on Thursday, August 6, 2026.

The Company will host a call the same day to discuss the results at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis’ website at www.axcelis.com, or by registering as a participant here: https://register-conf.media-server.com/register/BIf61211144e3b4baeb4c13ba3b1f529fa Webcast replays will be available for 30 days following the call.

About Axcelis:

Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

CONTACTS:

Investor Relations Contact:
David Ryzhik
Senior Vice President and Interim CFO
Telephone: (978) 787-2352
Email: David.Ryzhik@axcelis.com

Press/Media Relations Contact: 
Maureen Hart
Senior Director, Corporate & Marketing Communications
Telephone: (978) 787-4266
Email: Maureen.Hart@axcelis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/axcelis-announces-timing-and-availability-of-second-quarter-2026-results-and-conference-call-302831533.html

SOURCE Axcelis Technologies, Inc.

Continue Reading

Trending